Lupin’s share price surged up to 6.6%, hitting 52-week highs after stunning Q3 results.
A massive jump! From ₹153.4 crore to ₹613 crore in net profit during Oct-Dec.
Record sales in the US and global markets fuel Lupin’s growth, with North American sales climbing 23.7% year-on-year.
US sales hit $212 Million, surpassing expectations. 14 ANDA approvals and 3 new product launches in the US.
India sales up 13.4%, contributing 34% to global sales. Growth in LATAM, APAC, and strong 36% rise in EMEA.
EBITDA nearly doubles to ₹1,038 crore. Fourth consecutive quarter of more than doubling profits.
Total revenue rises 20.2% to ₹5,197.4 crore. Lupin scales new heights with robust growth across markets.